Novocure is a global oncology company that develops and commercializes proprietary Tumor Treating Fields (TTFields) therapy, which uses electric fields to kill cancer cells while leaving healthy tissue largely unaffected. The company markets three FDA-approved portable medical devices—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer—along with a pipeline product for brain metastases. Revenue is generated through monthly patient billing to private insurers, Medicare, and hospitals across multiple markets, with the largest revenue stream from Optune Gio in the United States, Germany, France, and Japan.